Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells $2,002,000.00 in Stock

Moderna, Inc. (NASDAQ:MRNAGet Rating) Director Noubar Afeyan sold 10,000 shares of Moderna stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $200.20, for a total transaction of $2,002,000.00. Following the sale, the director now directly owns 2,247,209 shares in the company, valued at approximately $449,891,241.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Noubar Afeyan also recently made the following trade(s):

  • On Wednesday, January 11th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $188.57, for a total transaction of $1,885,700.00.
  • On Wednesday, January 4th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $182.15, for a total transaction of $1,821,500.00.
  • On Wednesday, December 21st, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $201.70, for a total transaction of $2,017,000.00.
  • On Wednesday, December 14th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $195.00, for a total transaction of $1,950,000.00.
  • On Wednesday, December 7th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $172.16, for a total transaction of $1,721,600.00.
  • On Wednesday, November 30th, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $173.52, for a total transaction of $1,735,200.00.
  • On Wednesday, November 23rd, Noubar Afeyan sold 10,000 shares of Moderna stock. The stock was sold at an average price of $178.01, for a total transaction of $1,780,100.00.
  • On Wednesday, November 16th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $184.25, for a total transaction of $1,842,500.00.
  • On Wednesday, November 9th, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $162.50, for a total transaction of $1,625,000.00.
  • On Wednesday, November 2nd, Noubar Afeyan sold 10,000 shares of Moderna stock. The shares were sold at an average price of $154.20, for a total transaction of $1,542,000.00.

Moderna Stock Up 1.9 %

MRNA stock opened at $193.98 on Monday. Moderna, Inc. has a 52 week low of $115.03 and a 52 week high of $217.25. The company has a market capitalization of $74.52 billion, a price-to-earnings ratio of 7.02 and a beta of 1.71. The firm’s 50-day moving average is $185.39 and its two-hundred day moving average is $160.96. The company has a current ratio of 2.10, a quick ratio of 1.80 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNAGet Rating) last released its earnings results on Thursday, November 3rd. The company reported $2.53 EPS for the quarter, missing analysts’ consensus estimates of $3.04 by ($0.51). Moderna had a return on equity of 70.03% and a net margin of 55.00%. The business had revenue of $3.36 billion during the quarter, compared to the consensus estimate of $3.33 billion. On average, analysts forecast that Moderna, Inc. will post 21.31 earnings per share for the current fiscal year.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. Total Clarity Wealth Management Inc. bought a new stake in shares of Moderna in the 2nd quarter worth approximately $25,000. Ronald Blue Trust Inc. raised its holdings in shares of Moderna by 307.4% in the 4th quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock worth $26,000 after purchasing an additional 166 shares in the last quarter. Evoke Wealth LLC raised its holdings in shares of Moderna by 100.8% during the third quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock valued at $28,000 after acquiring an additional 120 shares during the period. Guardian Wealth Advisors LLC acquired a new stake in shares of Moderna during the third quarter valued at approximately $28,000. Finally, FinTrust Capital Advisors LLC raised its holdings in shares of Moderna by 754.5% during the second quarter. FinTrust Capital Advisors LLC now owns 188 shares of the company’s stock valued at $31,000 after acquiring an additional 166 shares during the period. 63.11% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on MRNA shares. Cowen decreased their price target on shares of Moderna from $165.00 to $145.00 in a report on Thursday, October 20th. SVB Leerink boosted their target price on shares of Moderna from $102.00 to $111.00 and gave the company a “market perform” rating in a research note on Wednesday, January 18th. Morgan Stanley boosted their target price on shares of Moderna from $170.00 to $209.00 and gave the company an “equal weight” rating in a research note on Friday, December 16th. Jefferies Financial Group raised shares of Moderna from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $275.00 in a research note on Monday, December 19th. Finally, Bank of America boosted their target price on shares of Moderna from $160.00 to $182.00 in a research note on Tuesday, November 15th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $191.92.

About Moderna

(Get Rating)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines.

See Also

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.